


A great mind with a big heart living a quality life, even with lung cancer.



Case report of a
61-year-old patient
with stage IV
metastatic
non-squamous
NSCLC &
liver metastases.
ECOG PS1



Mail this to me:

 **TECENTRIQ**[®]
atezolizumab

Tecentriq, in combination with Avastin, paclitaxel and carboplatin, is indicated for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.

*All medical and treatment details are from one IMpower 150 clinical trial patient. The name and personal details of the patient have been changed to protect patient confidentiality.

1L - mNSCLC

TECENTRIQ
+ AVASTIN
+ CARBOPLATIN
+ PACLITAXEL

MEDICAL HISTORY

Former smoker until 2011
1 pack/day for 30 years

Atrial fibrillation
Hyperuricaemia
Benign prostate hyperplasia

Laryngeal cancer
resolved 2011

Stage III NSCLC
completely resected,
6 cycles adjuvant
cisplatin + vinorelbine | 2013

DIAGNOSIS | 04.2016
STAGE IV NSCLC
ADDITIONAL LESIONS



Liver
metastases, including
3 large lesions

Parenchyma
numerous
small lesions

NEGATIVE MUTATIONS

EGFR | ALK
KRAS | ROS1
BRAF | HER2
MET-amp
PD-L1 IHC:
TC = 10%
IC = 1%

Enrolled in clinical trial

05.2016
IMpower150
Randomised to Arm B

4 cycles induction
TECENTRIO
+ AVASTIN
+ CARBOPLATIN
+ PACLITAXEL

Maintenance
TECENTRIO
+ AVASTIN

+ zoom

WEEK 1
Paclitaxel withdrawn
after 1st infusion



CT | target liver lesions



33% reduction vs baseline



33% reduction vs baseline



20
MONTHS
PR

01.2018
Progressive disease
due to new adrenal
gland lesion

Liver mets stable
2L chemotherapy
started



Patient safety summary

Treatment-related* AEs
Grade 1-2

Nausea

Peripheral neuropathy
(grade 3, paclitaxel withdrawn)

Diarrhoea

Neutro-/thrombo-
& leukopenia
grade 2-4, no change
to medication

Hypokalemia &
-magnesaemia

Arthralgia

Pain


*In opinion of investigator.
Treatment relationship may be
to one or more of atezolizumab,
bevacizumab, carboplatin or
paclitaxel



TECENTRIQ + Avastin + carbo/pac for chemotherapy-naïve non-squamous mNSCLC

A powerful regimen when patients need more

Deliver sustained survival in specific patient types^{1,5}



TECENTRIQ + Avastin + carbo/pac nearly doubled PFS benefit at 12 months³

- 12 months PFS was 38% with TECENTRIQ + Avastin + carbo/pac vs 20% with Avastin + carbo/pac alone (HR=0.59; 95% CI, 0.50, 0.69; P<0.0001)

A majority of patients responded to TECENTRIQ + Avastin + carbo/pac³

- ORR 56% (95% CI, 51.4, 61.4) with TECENTRIQ + Avastin + carbo/pac vs 41% (95% CI, 35.3, 45.2) with Avastin + carbo/pac alone

A manageable and familiar safety profile³

- 2.0% of patients experienced ≥ grade 3 bleeding events with TECENTRIQ + Avastin + carbo/pac vs 1.3% with Avastin + carbo/pac alone†

The first cancer immunotherapy combination to demonstrate meaningful OS in EGFR+ patients and patients with liver metastases*



References

1. Tecentriq India prescribing Information 2. Avastin India prescribing Information 3. Socinski MA, Jotte R, Cappuzzo F, et al; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301. 4. Data on file. Roche. 5. Nogami N et. al J Thorac Oncol. 2022 Feb;17(2):309-323.

® = Registered Trade Mark F. Hoffmann - La Roche Limited, Basel, Switzerland.

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.

Full prescribing information available on request.

For scientific information on Roche Medicinal Product please write to india.medinfo@roche.com

For all Adverse Events/Special Situation Reports with Roche Medicinal

Product please report the same to india.drugsafety@roche.com within one business day/24 hours.



http://bit.ly/Roche_Tecentriq_Avastin_PI

Please use the QR code/click on the link for the latest Prescribing Information (PI)



Roche Products (India) Pvt. Ltd,
146-B, 166 A, Unit No. 7, 8, 9,
8th Floor, R City Office, R City Mall,
Lal Bahadur Shastri Marg,
Ghatkopar, Mumbai - 400 086.
Maharashtra, India
Tel No. +91 22 50457300; Fax No, +91 22 50457301

M-IN-00002963
Expiration Date: 08/07/2024

 **TECENTRIQ®**
atezolizumab